{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T20:40:56Z","timestamp":1721853656594},"reference-count":29,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,4,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>This article has a companion Point by Peggs.<\/jats:p>","DOI":"10.1182\/bloodadvances.2017011130","type":"journal-article","created":{"date-parts":[[2018,4,10]],"date-time":"2018-04-10T12:00:14Z","timestamp":1523361614000},"page":"821-824","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Should all patients with HL who relapse after ASCT be considered for allogeneic SCT? A consult, yes; a transplant, not necessarily"],"prefix":"10.1182","volume":"2","author":[{"given":"Craig H.","family":"Moskowitz","sequence":"first","affiliation":[{"name":"Division of Hematologic Oncology, Lymphoma Service, and Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; and Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2018,4,10]]},"reference":[{"issue":"12","key":"2019111616370722500_B1","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1093\/annonc\/mdw421","article-title":"Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed\/refractory Hodgkin\u2019s lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"27","author":"Genadieva-Stavrik","year":"2016","journal-title":"Ann Oncol"},{"issue":"2","key":"2019111616370722500_B2","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3324\/haematol.2011.045757","article-title":"Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin\u2019s lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espa\u00f1ol de Linfomas\/Trasplante de M\u00e9dula Osea (GEL\/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"97","author":"Sureda","year":"2012","journal-title":"Haematologica"},{"issue":"8","key":"2019111616370722500_B3","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1200\/JCO.2010.32.1711","article-title":"Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin\u2019s lymphoma","volume":"29","author":"Peggs","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111616370722500_B4","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ijrobp.2017.05.007","article-title":"Role of consolidative radiation therapy after autologous hematopoietic cell transplantation for the treatment of relapsed or refractory hodgkin lymphoma","volume":"99","author":"Wilke","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2019111616370722500_B5","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ijrobp.2010.05.010","article-title":"Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed\/refractory Hodgkin lymphoma?","volume":"81","author":"Kahn","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2019111616370722500_B6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0360-3016(96)00277-5","article-title":"High-dose therapy and autologous bone marrow transplantation for relapsed\/refractory Hodgkin\u2019s disease: the impact of involved field radiotherapy on patterns of failure and survival","volume":"36","author":"Poen","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"2019111616370722500_B7","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.ijrobp.2017.01.222","article-title":"Accelerated total lymphoid irradiation-containing salvage regimen for patients with refractory and relapsed Hodgkin lymphoma: 20 years of experience","volume":"97","author":"Rimner","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16","key":"2019111616370722500_B8","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"issue":"17","key":"2019111616370722500_B9","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"2019111616370722500_B10","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med"},{"issue":"18","key":"2019111616370722500_B11","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111616370722500_B12","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1182\/blood-2014-08-595801","article-title":"Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Gopal","year":"2015","journal-title":"Blood"},{"key":"2019111616370722500_B13","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/asheducation-2016.1.331","article-title":"Novel agents and strategies in transplant-eligible patients with relapsed and refractory Hodgkin lymphoma","volume":"2016","author":"Moskowitz","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"9980","key":"2019111616370722500_B14","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"issue":"31","key":"2019111616370722500_B15","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILUre","volume":"34","author":"Armand","year":"2016","journal-title":"J Clin Oncol"},{"issue":"19","key":"2019111616370722500_B16","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111616370722500_B17","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111616370722500_B18","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"2019111616370722500_B19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1189\/jlb.1212621","article-title":"At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy","volume":"94","author":"Intlekofer","year":"2013","journal-title":"J Leukoc Biol"},{"issue":"21","key":"2019111616370722500_B20","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms","volume":"25","author":"Parry","year":"2005","journal-title":"Mol Cell Biol"},{"issue":"8","key":"2019111616370722500_B21","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion [published correction appears in Nat Med. 2002;8:1039]","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"issue":"4","key":"2019111616370722500_B22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrclinonc.2016.168","article-title":"PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas","volume":"14","author":"Goodman","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"23","key":"2019111616370722500_B23","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"issue":"23","key":"2019111616370722500_B24","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"19","key":"2019111616370722500_B25","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"2019111616370722500_B26","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.hemonc.2016.12.002","article-title":"Relapse of Hodgkin lymphoma after autologous transplantation: Time to rethink treatment?","volume":"10","author":"Jethava","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"10","key":"2019111616370722500_B27","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","article-title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma","volume":"129","author":"Merryman","year":"2017","journal-title":"Blood"},{"issue":"18","key":"2019111616370722500_B28","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1182\/blood-2016-11-749556","article-title":"Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma","volume":"129","author":"Herbaux","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2019111616370722500_B29","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1182\/blood-2017-01-761346","article-title":"PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD","volume":"130","author":"Haverkos","year":"2017","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/7\/821\/880612\/advances011130.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/7\/821\/880612\/advances011130.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T16:37:23Z","timestamp":1573922243000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/2\/7\/821\/15807\/Should-all-patients-with-HL-who-relapse-after-ASCT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,10]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,4,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2017011130","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,10]]}}}